TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12239447
Drug: Vinblastine (VBL)
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinblastine (VBL) 0.15 mg/kg i.v. every 2 weeks, Interferon-gamma (IFN-gamma) 100 microg s.c. 3 times weekly, and oral 13-cis retinoic acid (13-CRA) 40 mg/day (Trial 2)
Study: 8960727
Drug: Oral 3,4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 3,4 diaminopyridine (DAP)
Study: 1561829
Drug: Split-product influenza
Normalized name: INFLUENZA VIRUS (SPLIT) VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-product influenza vaccine in full-term children
Study: 30366845
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy trials with funding, conducted in Europe and Oceania, and with a Physiotherapy Evidence Database score of at least 6/10
Study: 30366845
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy trials
Study: 24928639
Drug: 6 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 sessions of spinal manipulative therapy (SMT)
Study: 25533998
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ramelteon
Study: 17373561
Drug: Integrated Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Cognitive Behavioral Treatment (ICBT)
Study: 20455882
Drug: Everolimus 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 1.5 mg/day with reduced-exposure CsA
Study: 20455882
Drug: Everolimus 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 3.0 mg/day with reduced-exposure CsA
Study: 20455882
Drug: Mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolic acid (MPA) 1.44 g/day plus standard-exposure CsA
Study: 12142815
Drug: Ranitidine 5
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 5 mg/kg daily
Study: 12142815
Drug: Ranitidine 10
Normalized name: ranitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 10 mg/kg daily
Study: 9663727
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily
Study: 973959
Drug: Pindolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (5 mg)
Study: 15933496
Drug: Local corticosteroid
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local corticosteroid injection
Study: 30204859
Drug: Intensive nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive nutritional intervention (weekly dietetic consultation, energy-protein-enriched diet, and ONS 400 mL per day for 3 months)
Study: 26576820
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (cognitive behavior therapy and fluoxetine)
Study: 2220335
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radiographic techniques
Study: 366350
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone dipropionate (300 microgram/day)
Study: 28922519
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil treatment
Study: 28922519
Drug: HOFA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOFA treatment
Study: 20502929
Drug: L. paracasei
Normalized name: L. paracasei/L. rhamnosus 11 billion cell ORAL CAPSULE
DrugBank: Lactobacillus paracasei (DB16551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. paracasei GMNL‐33
Study: 19905943
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment (scaling and root planing) before 21 weeks of gestation
Study: 17970675
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (periodontal treatment after delivery)
Study: 30569067
Drug: Native whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native whey (20 g)
Study: 30569067
Drug: WPC‐80 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: WPC‐80 (20 g)
Study: 15602190
Drug: Albendazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (15 mg/kg/day twice a day for 7 days)
Study: 24449228
Drug: SRP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP and oral doxycycline (100 mg) administration once daily for 15 days
Study: 16580190
Drug: Urokinase (125,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase (125,000 UI) administered via intrathoracic tube every 12 hours until pleural fluid < 50 cm3
Study: 16580190
Drug: Urokinase (125,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase (125,000 UI) administered via intrathoracic tube
Study: 10784638
Drug: Dexamethasone 2
Normalized name: dexamethasone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 2 mg orally three times a day (tid)
Study: 8729590
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg twice daily, starting at least 2 weeks before PTCA
Study: 1343609
Drug: Ciprofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (250 mg daily for 6 months)
Study: 1343609
Drug: Trimethoprim-sulfamethoxazole (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (80 mg trimethoprim, 400 mg sulfamethoxazole daily for 6 months)
Study: 8527269
Drug: MK-0591 (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0591 (125 mg twice daily for 9.5 days)
Study: 8527269
Drug: MK-0591 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0591 (250 mg single dose)
Study: 28659234
Drug: Ginger (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (250 mg ginger capsules from the onset of menstruation)
Study: 25835438
Drug: High-Intensity Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Statin Therapy (HIST)
Study: 25835438
Drug: Low-Intensity Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Statin Therapy (LIST)
Study: 25835438
Drug: No-Statin Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-Statin Therapy
Study: 15138463
Drug: 15 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/day alcohol
Study: 15138463
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day alcohol
Study: 15138463
Drug: 0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g/day alcohol (control)
Study: 11477813
Drug: Purified Xuefu
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Xuefu Capsule (PXFC) and western medicine
Study: 11477813
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (isosorbide dinitrate, diltiazem or atenolol)
Study: 11477813
Drug: Purified Xuefu
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Xuefu Capsule (PXFC)
Study: 667231
Drug: Haloperidol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.5 mg injection)
Study: 27678433
Drug: Oral-fat tolerance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-fat tolerance test (OFTT)
Study: 27678433
Drug: Oral-fat tolerance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-fat tolerance test (OFTT) in CORDIOPREV study
Study: 23877305
Drug: Single shot
Normalized name: ACL7 SINGLE SHOT EPIDURAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single shot femoral nerve block (FNB) using 15mL bupivacaine 0.25% and 20 mg clonidine
Study: 20552926
Drug: Gabapentin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (up to 900 mg/d)
Study: 20552926
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or lowest dose of gabapentin (300 mg/d)
Study: 12461037
Drug: Azithromycin administered
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin administered alone
Study: 12461037
Drug: Ceftriaxone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone administered alone
Study: 12461037
Drug: Azithromycin and
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin and ceftriaxone administered concurrently
Study: 12461037
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (azithromycin and ceftriaxone administered alone)
Study: 10656205
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg b.i.d.) and 1000 IU vitamin D3
Study: 10656205
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg b.i.d.) and 1000 IU vitamin D3 with retarded-release sodium fluoride (25 mg t.i.d.)
Study: 1888048
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (100 micrograms in 10 ml isotonic saline)
Study: 18243724
Drug: Furosemide at
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide at 4 mg/h
Study: 18243724
Drug: Saline at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline at 2 ml/h (Control)
Study: 10188139
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (uvulopalatopharyngoplasty with or without mandibular osteotomy)
Study: 6805243
Drug: 20/250 combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/250 combination of ethinylestradiol and levonorgestrel
Study: 6805243
Drug: 30/250 combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30/250 combination of ethinylestradiol and levonorgestrel
Study: 6805243
Drug: 30/150 combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30/150 combination of ethinylestradiol and levonorgestrel
Study: 6805243
Drug: Triphasic drug
Normalized name: Tribasic Calcium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic drug combination of ethinylestradiol and levonorgestrel
Study: 17324531
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation
Study: 21844495
Drug: Carboplatin plus
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin plus pegylated liposomal doxorubicin (PLD) 30 mg/m²
Study: 19659999
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg day(-1) for 12 weeks)
Study: 12145173
Drug: L-NMMA (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (6 mg/kg total dose)
Study: 2176815
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml 1.4% mepivacaine with epinephrine (1:200,000) and 4 mEq of NaHCO3
Study: 2176815
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml 1.4% mepivacaine with epinephrine (1:200,000)
Study: 7467378
Drug: K. H.
Normalized name: Ketamine Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: K. H. 3 (medication)
Study: 6538013
Drug: Intravenous alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alcohol administration
Study: 10624640
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg lidocaine 2% mixed with 0.5 mg/kg bupivacaine 0.5% without epinephrine (pH = 6.3)
Study: 10624640
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg lidocaine 2% mixed with 0.5 mg/kg bupivacaine 0.5% with 8.4% sodium bicarbonate (mean final pH = 6.90)
Study: 10624640
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg lidocaine 2% mixed with 0.5 mg/kg bupivacaine 0.5% with 8.4% sodium bicarbonate (mean final pH = 7.16)
Study: 10624640
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg lidocaine 2% mixed with 0.5 mg/kg bupivacaine 0.5% with 8.4% sodium bicarbonate (mean final pH = 7.43)
Study: 2109497
Drug: Antidepressant with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant with predominant serotoninergic action (indalpine or citalopram)
Study: 2109497
Drug: Noradrenergic antidepressant
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noradrenergic antidepressant (maprotiline)
Study: 29323626
Drug: Daily mood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mood chart app program (control group)
Study: 15366587
Drug: Yigu capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yigu capsule (YGC)
Study: 9849010
Drug: Concurrent chemo-radiotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemo-radiotherapy (CT + RT)
Study: 28139220
Drug: Drug-Eluting Balloons
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Balloons (DEB) for DES-ISR
Study: 28139220
Drug: Drug-Eluting Balloons
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Eluting Balloons (DEB) for BMS-ISR
Study: 16629894
Drug: Enzymatic commercial
Normalized name: hydrolyzed sericin (enzymatic; 2500 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzymatic commercial solution (Ortoform)
Study: 11411816
Drug: Ziprasidone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone treatment
Study: 18293201
Drug: MgSO(4) continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO(4) continuous infusion for 24 hours postpartum (Group A)
Study: 18293201
Drug: MgSO(4) administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MgSO(4) administration discontinued when urinary output was > or =100 ml/hr for 2 consecutive hours (Group B)
Study: 6342959
Drug: Metronidazole suppositories
Normalized name: metronidazole Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole suppositories (short-term use for 72 hours)
Study: 21164546
Drug: β‐glucan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐glucan (100 mg, Imunoglukan) supplementation
Study: 7845115
Drug: Single course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single course of portal infusion with mitomycin (10 mg/m2, one dose) plus fluorouracil (500 mg/m2 per 24 h for 7 days)
Study: 2140842
Drug: Dim light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim light therapy (50 lux)
Study: 30572281
Drug: Ultrasound-guided platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided platelet-rich plasma (PRP) injection
Study: 23344509
Drug: Pregabalin 600
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 600 mg per os divided in two doses
Study: 17376305
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with terazosin 2 mg once daily and tolterodine 2 mg twice daily for 6 weeks
Study: 17376305
Drug: Terazosin 2
Normalized name: terazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin 2 mg once daily for 6 weeks
Study: 15264729
Drug: Crystalloid coload
Normalized name: influenza B virus B/Colorado/06/2017 antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid coload (20 ml x kg(‐1) of crystalloid solution by rapid infusion immediately after induction)
Study: 15264729
Drug: Crystalloid preload
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid preload (20 ml x kg(‐1) of crystalloid solution during 20 minutes prior to induction)
Study: 522637
Drug: Oxprenolol 40
Normalized name: oxprenolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol 40 mg
Study: 30829017
Drug: Antidepressant drug
Normalized name: MAO A Inhibitors, antidepressant drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant drug use in PES group (n=3, 4.1%)
Study: 30829017
Drug: Antidepressant drug
Normalized name: MAO A Inhibitors, antidepressant drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant drug use in non-PES non-glaucoma group (n=21, 1.1%)
Study: 30829017
Drug: Medications for
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications for hypertension in PES group
Study: 30829017
Drug: Medications for
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications for coronary artery disease in PES group
Study: 24460655
Drug: Deferasirox (9.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (9.7 ± 3.0 mg/kg/d)
Study: 21187622
Drug: 1.23% APF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.23% APF gel iontophoresis
Study: 9684120
Drug: High-dose branched
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose branched chain amino acid-enriched solution
Study: 7601179
Drug: Nimesulide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide (100 mg bid)
Study: 7601179
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (550 mg bid)
Study: 28041917
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) combined with Vocational Rehabilitation (VR)
Study: 22923150
Drug: Micro dose
Normalized name: Lipantil Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro dose GnRH agonist protocol
Study: 14695934
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg coenzyme Q10
Study: 14695934
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg coenzyme Q10
Study: 10955324
Drug: DR4/1 peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: DR4/1 peptide injections every 6 weeks
Study: 10955324
Drug: DR4/1 peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: DR4/1 peptide injections every 8 weeks
Study: 8617186
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g lactitol in milk chocolate
Study: 8617186
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g isomalt in milk chocolate
Study: 8617186
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g maltitol in milk chocolate
Study: 8617186
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g maltitol in milk chocolate
Study: 8339411
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg flosequinan twice daily
Study: 23981504
Drug: Topical microemulsion
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical microemulsion
Study: 11044499
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (rollerball or resection)
Study: 20443731
Drug: Q‐TER(®), 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q‐TER(®), 160 mg, once a day for 30 days
Study: 20443731
Drug: Vitamin E,
Normalized name: GRx Vitamin E, topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin E, 50 mg, once a day for 30 days
Study: 10509550
Drug: Felodipine-metoprolol combination
Normalized name: felodipine / metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine-metoprolol combination tablet (Logimax), 5/50 mg daily
Study: 10509550
Drug: Enalapril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 10 mg daily
Study: 1563195
Drug: Temperature measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temperature measurement (AUC calculated from rectal temperature measurements one to four times a day)
Study: 4077506
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment with the duo formula (12 sessions over 3 months)
Study: 31484661
Drug: Cellphone-based daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellphone-based daily medication and weekly pill refilling reminders in addition to usual care
Study: 30134283
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg oxycodone alone (Group C)
Study: 30134283
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg oxycodone + 2.4 μg/kg DEX (Group D1)
Study: 26659543
Drug: GHB 35
Normalized name: GHB
DrugBank: gamma-Hydroxybutyric acid (DB01440)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHB 35 mg kg(‐1)
Study: 24115072
Drug: ONO-5334 sustained
Normalized name: ONO-5334
DrugBank: ONO-5334 (DB19206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-5334 sustained release tablet (SRT)
Study: 24115072
Drug: ONO-5334 immediate
Normalized name: ONO-5334
DrugBank: ONO-5334 (DB19206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-5334 immediate release tablet (IRT)
Study: 23047652
Drug: Pomegranate extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate extract (1-g capsule)
Study: 29861448
Drug: MAG-DHA (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAG-DHA (8 × 625 mg softgels daily for 60 days)
Study: 26758884
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (TIO) 18 µg once daily
Study: 26758884
Drug: Aclidinium (ACL)
DrugBank: Aclidinium (DB08897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium (ACL) 322 µg twice daily
Study: 7617806
Drug: Fluoxetine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (40 mg daily)
Study: 31479306
Drug: Low-dose tamoxifen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tamoxifen
Study: 23743969
Drug: Guayakí Yerba
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guayakí Yerba Maté Organic Energy Shot™ (YM; 140 mg caffeine)